![]() Standard of care in recurrent metastatic disease. The first trial that was reported was the JAVELIN trial, and this looked at cisplatin radiation, either with the PD-L1 inhibitor avelumab or with placebo, and in that trial, not only did avelumab not improve outcome, there was actually a non-statistically but numerically apparent worsening in both progression-free survival and overall survival with the hazard ratio for progression of 1.21 for the avelumab arm.Ī very similar, large, randomized phase 3 study was done with the PD-1 inhibitor, pembrolizumab, and so this is an agent that’s better validated in head and neck cancer. Unfortunately, they haven’t provided the step forward that we anticipated. I think we had been full of hope that the answer to that question would come from immunotherapy, and there have been some randomized trials that looked at immune checkpoint inhibition integrated with chemoradiation or with radiation in the locally advanced setting. So I think the most pressing need is for advances that will increase the cure rate and that will do so in the difficult, treatment-resistant, HPV-negative population. Although they have initial disease control, there’s disease recurrence, and many patients succumb to head and neck cancer. ![]() But it’s also the case that many patients, and particularly those with HPV-negative disease, are not cured. Well, many patients who are treated with combined modality therapy for locally advanced head and neck squamous cell carcinoma are cured and for those patients, I think our highest need is for therapies that are less toxic. ![]() Burtness, first and foremost, what are the unmet needs associated with managing locally advanced squamous cell carcinoma? And what are some of the more interesting data from recent clinical trials? We’ll look at the challenges, current treatment landscape, and some exciting new data for a novel approach to treatment using an inhibitor of apoptosis protein antagonists. Ari Rosenberg, and we will be discussing locally advanced squamous cell carcinoma of the head and neck. Prior to beginning the activity, please be sure to review the faculty and commercial support disclosure statements as well as the learning objectives. This activity, entitled “Innovations in the Treatment of Locally Advanced Squamous Cell Carcinoma of Head and Neck: Enhancing Antitumor Activity Through Inhibitor of Apoptosis Protein Antagonism” is provided by Agile.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |